Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
We may earn a commission from links on this page. Deal pricing and availability subject to change after time of publication. Black Friday sales officially start Friday, November 28, and run through ...
TL;DR: Microsoft Visio is now only $9.97 (reg. $249.99). Sometimes, it takes a good visual to explain a complex set of data, but you don’t need a design degree to make that happen. Instead, use ...
remove-circle Internet Archive's in-browser video "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see your ...
Embark on a fulfilling pharmacy career with our Pharmacy Technician Training Program. Our 16-week program allows you to gain the skills required for safe patient care. The self-paced format ensures ...
Abstract: In this brief, for time-varying nonlinear systems, a novel approximate dynamic programming structure is first proposed to obtain the approximate optimal solution of the control system. In ...
An exercise-driven course on Advanced Python Programming that was battle-tested several hundred times on the corporate-training circuit for more than a decade. Written by David Beazley, author of the ...
Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback